(Press-News.org) The European Space Agency-led Solar Orbiter mission has split the flood of energetic particles flung out into space from the Sun into two groups, tracing each back to a different kind of outburst from our star.
The Sun is the most energetic particle accelerator in the Solar System. It whips up electrons to nearly the speed of light and flings them out into space, flooding the Solar System with so-called ‘Solar Energetic Electrons’ (SEEs).
Researchers have now used Solar Orbiter to pinpoint the source of these energetic electrons and trace what we see out in space back to what’s actually happening on the Sun. In a paper to be published in Astronomy & Astrophysics on 1 September, they explain that they found two kinds of SEE with clearly distinct stories: one connected to intense solar flares (explosions from smaller patches of the Sun’s surface), and one to larger eruptions of hot gas from the Sun’s atmosphere (known as ‘coronal mass ejections’, or CMEs).
“We see a clear split between ‘impulsive’ particle events, where these energetic electrons speed off the Sun’s surface in bursts via solar flares, and ‘gradual’ ones associated with more extended CMEs, which release a broader swell of particles over longer periods of time,” says lead author Alexander Warmuth of the Leibniz Institute for Astrophysics Potsdam (AIP), Germany.
A clearer connection
While scientists were aware that two types of SEE event existed, Solar Orbiter was able to measure a large number of events, and look far closer to the Sun than other missions had, to reveal how they form and leave the surface of our star.
“We were only able to identify and understand these two groups by observing hundreds of events at different distances from the Sun with multiple instruments – something that only Solar Orbiter can do,” adds Alexander. “By going so close to our star, we could measure the particles in a ‘pristine’ early state and thus accurately determine the time and place they started at the Sun.”
Flight delays
The researchers detected the SEE events at different distances from the Sun. This let them study how the electrons behave as they travel through the Solar System, answering a lingering question about these energetic particles.
When we spot a flare or a CME, there’s often an apparent lag between what we see taking place at the Sun, and the release of energetic electrons into space. In extreme cases, the particles seem to take hours to escape. Why?
“It turns out that this is at least partly related to how the electrons travel through space – it could be a lag in release, but also a lag in detection,” says co-author and ESA Research Fellow Laura Rodríguez-García. “The electrons encounter turbulence, get scattered in different directions, and so on, so we don’t spot them immediately. These effects build up as you move further from the Sun.”
The space between the Sun and the planets of the Solar System isn’t empty. A wind of charged particles streams out from the Sun constantly, dragging the Sun’s magnetic field with it. It fills space and influences how the energetic electrons travel; rather than being able to go where they like, they are confined, scattered, and disturbed by this wind and its magnetism.
The study fulfils an important goal of Solar Orbiter: to continuously monitor our star and its surroundings to trace ejected particles back to their sources at the Sun.
“Thanks to Solar Orbiter, we’re getting to know our star better than ever,” says Daniel Müller, ESA Project Scientist for Solar Orbiter. “During its first five years in space, Solar Orbiter has observed a wealth of Solar Energetic Electron events. As a result, we’ve been able to perform detailed analyses and assemble a unique database for the worldwide community to explore.”
Keeping Earth safe
Crucially, the finding is important for our understanding of space weather, where accurate forecasting is essential to keep our spacecraft operational and safe. One of the two kinds of SEE events is more important for space weather: that connected to CMEs, which tend to hold more high-energy particles and so threaten far more damage. Because of this, being able to distinguish between the two types of energetic electrons is hugely relevant for our forecasting.
“Knowledge such as this from Solar Orbiter will help protect other spacecraft in the future, by letting us better understand the energetic particles from the Sun that threaten our astronauts and satellites,” adds Daniel. “The research is a really great example of the power of collaboration – it was only possible due to the combined expertise and teamwork of European scientists, instrument teams from across ESA Member States, and colleagues from the US.”
Looking ahead, ESA's Vigil mission will pioneer a revolutionary approach, operationally observing the 'side' of the Sun for the first time, unlocking continuous insights into solar activity. To be launched in 2031, Vigil will detect potentially hazardous solar events before they come into view as seen from Earth, giving us advance knowledge of their speed, direction and chance of impact.
Our understanding of how our planet responds to solar storms will also be investigated further with the launch of ESA’s Smile mission next year. Smile will study how Earth endures the relentless ‘wind’, and sporadic bursts, of fierce particles thrown our way from the Sun, exploring how the particles interact with our planet's protective magnetic field.
Solar Orbiter is a space mission of international collaboration between ESA and NASA, operated by ESA.
Notes for editors
‘CoSEE-Cat: a Comprehensive Solar Energetic Electron event Catalogue obtained from combined in-situ and remote-sensing observations from Solar Orbiter’ by A. Warmuth et al. is published today in Astronomy & Astrophysics. The results are compiled in a publicly accessible online event catalogue, the Comprehensive Solar Energetic Electron event Catalogue (CoSEE-Cat): https://coseecat.aip.de/
More information on the capabilities and leading institutions for each of the instruments used in this study – EPD, STIX, EUI, RPW, Metis, SoloHI, SWA, and MAG – is available here: https://www.esa.int/ESA_Multimedia/Images/2020/01/Solar_Orbiter_s_instruments
More about Solar Orbiter: https://www.esa.int/Science_Exploration/Space_Science/Solar_Orbiter
More about Vigil: https://www.esa.int/Space_Safety/Vigil
More about Smile: https://www.esa.int/Science_Exploration/Space_Science/Smile
Visit ESA’s Space Weather Service Network: https://swe.ssa.esa.int/ or read more about ESA’s space weather activities: https://www.esa.int/Space_Safety/Space_weather
END
Solar Orbiter traces superfast electrons back to Sun
2025-09-01
ELSE PRESS RELEASES FROM THIS DATE:
GaN-based electron beam technology from Nagoya University startup poised to overcome critical semiconductor manufacturing challenges at KIOXIA
2025-09-01
NAGOYA, Japan — In late September 2025, KIOXIA Iwate Corporation (Koichiro Shibayama CEO) will begin evaluating a GaN-based e-beam technology developed through joint research between Photo electron Soul Inc. (PeS; Takayuki Suzuki CEO), a Nagoya University startup, and the Amano–Honda Laboratory at Nagoya University.
PeS has developed a next-generation electron gun specialized for GaN (gallium nitride) photocathodes and has demonstrated its effectiveness for semiconductor inspection and metrology (I&M), enabling electron microscopy of nanoscale transistors and high-aspect-ratio structures.
These ...
Circle versus rectangle: Finding ‘Earth 2.0’ may be easier using a new telescope shape
2025-09-01
by Prof Heidi Newberg
The Earth supports the only known life in the universe, all of it depending heavily on the presence of liquid water to facilitate chemical reactions. While single-celled life has existed almost as long as the Earth itself, it took roughly three billion years for multicellular life to form. Human life has existed for less than one 10 thousandth of the age of the Earth.
All of this suggests that life might be common on planets that support liquid water, but it might be uncommon to find life that studies the universe and seeks to travel ...
Metformin changes blood metal levels in humans
2025-09-01
The widely used diabetes drug metformin changes blood metal levels in humans. The Kobe University study is an important step in understanding the drug’s many actions and designing better ones in the future.
Metformin is the most widely prescribed diabetes drug in the world. Apart from lowering blood sugar levels, it is also known to have a broad range of beneficial side effects such as against tumors, inflammations and atherosclerosis. However, although it has been used for more than 60 years ...
Long-term anticoagulation discontinuation after catheter ablation for atrial fibrillation
2025-08-31
About The Study: Among patients without documented atrial arrhythmia recurrence after catheter ablation for atrial fibrillation, discontinuing oral anticoagulant therapy resulted in a lower risk for the composite outcome of stroke, systemic embolism, and major bleeding vs continuing direct oral anticoagulant therapy.
Corresponding Author: To contact the corresponding author, Boyoung Joung, MD, email cby6908@yuhs.ac.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
Editor’s Note: Please see the article for additional information, including other authors, author contributions and ...
Fractional flow reserve–guided complete vs culprit-only revascularization in non–ST-elevation myocardial infarction and multivessel disease
2025-08-31
About The Study: Fractional flow reserve-guided complete revascularization during the index procedure resulted in a significant reduction in the composite of all-cause death, nonfatal myocardial infarction, any revascularization, and stroke at 1 year. This was mainly driven by reduced repeat revascularization.
Corresponding Author: To contact the corresponding author, Tobias F. S. Pustjens, MD, email t.pustjens@gmail.com.
To access the embargoed study: Visit our For The Media website at this link ...
Participation of women in cardiovascular trials from 2017 to 2023
2025-08-31
About The Study: The findings of this study highlight both progress and persistent challenges in representation of women within cardiovascular trials. These gaps not only limit the generalizability of trial outcomes but also perpetuate inequities in evidence-based care for women with cardiovascular conditions.
Corresponding Author: To contact the corresponding author, Martha Gulati, MD, MS, email martha.gulati@csmc.edu.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
Editor’s Note: Please see the article for ...
Semaglutide and tirzepatide in patients with heart failure with preserved ejection fraction
2025-08-31
About The Study: In patients with cardiometabolic heart failure with preserved ejection fraction, semaglutide and tirzepatide showed more than 40% risk reduction for the composite of hospitalization for heart failure or all-cause mortality compared with a placebo proxy. Tirzepatide showed no meaningful benefit over semaglutide.
Corresponding Author: To contact the corresponding author, Nils Krüger, MD, email nkruger1@bwh.harvard.edu.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
Editor’s Note: Please ...
Changes in biology of internal fat may be the leading cause of heart failure
2025-08-31
Heart failure with preserved ejection fraction (HFpEF) appears to develop as a result of changes in the biology of a person’s internal fat tissue, according to the Adipokine Hypothesis, a new way of understanding how fat may impact the heart. The hypothesis paper was published today in JACC, the flagship journal of the American College of Cardiology, and is being presented at ESC Congress 2025. The author of the paper is Milton Packer, MD, FACC, Distinguished Scholar in Cardiovascular Science at Baylor University Medical Center at Dallas and Visiting Professor at Imperial College in London.
“Up ...
Transcatheter or surgical treatment of patients with aortic stenosis at low to intermediate risk
2025-08-30
About The Study: In this individual participant data meta-analysis of 4 randomized clinical trials (RCTs), and an overall meta-analysis of 8 RCTs of patients with severe symptomatic aortic stenosis at low to intermediate risk, transcatheter aortic valve implantation (TAVI) was associated with a reduction in the 1-year incidence of all-cause death or any stroke. These findings emphasize TAVI as alternative option in patients at low to intermediate risk. Long-term follow-up is warranted to evaluate sustainability of these findings.
Corresponding Authors: To contact the corresponding authors, email Moritz Seiffert, MD, (moritz.seiffert@bergmannsheil.de) and ...
Promising new drug for people with stubborn high blood pressure
2025-08-30
A new treatment has been shown to significantly lower blood pressure in people whose levels stay dangerously high, despite taking several existing medicines, according to the results of a Phase III clinical trial led by a UCL Professor.
Globally around 1.3 billion people have high blood pressure (hypertension), and in around half of cases the condition is uncontrolled or treatment resistant. These individuals face a much greater risk of heart attack, stroke, kidney disease, and early death. In the UK the number of people with hypertension is around 14 ...